[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"irritable-bowel-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:irritable-bowel-syndrome":598},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,80,0,25,[9,47,72,96,125,146,170,190,213,233,256,275,305,330,353,374,392,424,442,463,487,513,536,558,577],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100570402",false,"NCT06706778","The Mechanism Underlying the Analgesic Effect of the Music of IBS Pain","Impacts of Music-based Intervention on Pain in Individuals With Irritable Bowel Syndrome (IBS): A Mechanistic Pilot Study","Inclusion Criteria:\n\n* aged between 18 and 50 years old,\n* can speak and read English,\n* having a confirmed diagnosis of IBS from a healthcare provider,\n* having experienced moderate pain (≥3 out of 10 on a numeric rating scale) at least four days a week for the past three months,\n* be willing to participate in a 4-week intervention and attend two lab visits, and\n* having daily access to an internet-enabled device for MBI.\n\nExclusion Criteria:\n\n* having a severe psychiatric disorder requiring inpatient treatment in the past six months,\n* regularly using opioids or illicit substances, or have used probiotics or antibiotics within two weeks prior to enrollment,\n* having celiac disease, inflammatory bowel disease, or a history of major gastrointestinal surgery,\n* concurrently participate in another IBS-related intervention study.","ALL","18 Years","50 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The proposed pilot study aims to assess the underlying mechanisms of the MBI on IBS pain and the feasibility of using novel technology in the outcome measurements. The specific aims of this pilot mechanistic clinical trial are to:\n\n1. . identify the mechanisms underlying the impact of MBI on IBS-related pain, stress responses, quantitative pain sensitivity, and gut microbiome profiles.\n2. . evaluate the technological feasibility of using a wearable abdominal sensor belt and smartwatch system in measuring MBI impacts on pain in home settings.\n\nResearchers will conduct a one-arm pre- and post-music intervention among patients with Irritable Bowel Syndrome, collect the IBS pain mechanistic biobehavioral markers, and analyze the underlying pathways of the music analgesic effect.\n\nParticipants will be asked to:\n\n1. . engage in a 4-week intervention of 20 minutes, both during the day and at night, for at least five days per week.\n2. . have two one-hour lab visits",[27,28],"Abdominal Pain\u002F Discomfort","Irritable Bowel Syndrome",[30,31,32,33,28],"abdominal pain","Music","Brain-gut axis","Stress","NOT_YET_RECRUITING","2026-06-30",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":21},"2026-08",{"date":42,"type":21},"2027-03",{"name":44,"class":45},"Yale University","OTHER",1,{"id":48,"slug":4,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":46},"100547825","NCT06413004","Brachyspira and Intestinal Allergy-like Immune Reactions in Patients With Irritable Bowel Syndrome (IBS)","Inclusion Criteria:\n\n* Patients with IBS diagnosis according to their treating physician (ROME IV).\n* Association between intake of food and GI symptoms.\n* Witnessed written informed consent prior to any study procedures.\n* Patients who are capable to understand the study and the questionnaires, and to comply with the study requirements.\n\nExclusion Criteria:\n\n* Patients with relevant concurrent organic GI disease (inflammatory bowel disease, abdominal cancer), or a major disease such as diabetes, uncontrolled thyroid disease, heart disease, kidney disease, liver disease, and active malignant disease (not those that were in remission at least 5 years).\n* Patients with a history of bowel surgery (not appendectomy or cholecystectomy) that affects GI motility.\n* Patients with systemic food allergy as evidenced by positive allergy tests (blood, prick test).\n* Clinical history of severe allergic reactions.\n* Patients with concurrent major confounding condition(s) based on the clinician's judgement, e.g. DOMINANT psychiatric disorder, vital depression, alcohol or substance abuse in the last 2 year.\n* Female patients who are pregnant or lactating (females of fertile age are requested to use a safe contraceptive) at the time of inclusion.\n* Patients who use or used new medications that affect the GI functioning within 1 month before the start of the study.","70 Years",{"count":54,"type":21},200,[24],"The aim of this study is to define local immune responses in the GI tract to food antigens in IBS patients, with and without Brachyspira infection, using advanced imaging. We hypothesize that Brachyspira infection can cause IBS symptoms by inducing loss of oral tolerance to dietary antigens through development of food-specific intestinal immune reactions and subsequent development of visceral hypersensitivity.\n\nDuring this study, the investigators will perform confocal laser endomiscroscopy (CLE) and\u002For colonoscopic antigen provocation test (COLAP) to test to which food items the participants react to. Furthermore, the investigators will perform rectal barostat examination and a sigmoidoscopy without laxatives. The investigators will collect biological samples and the participants will complete several questionnaires.",[28,58],"Food Sensitivity",[28,58,60,61],"Confocal Laser Endomicroscopy","Colonoscopic Antigen Provocation Test","RECRUITING","2026-06-24",{"date":65,"type":38},"2026-06-29",{"date":67,"type":38},"2022-08-03",{"date":69,"type":21},"2027-12-01",{"name":71,"class":45},"Magnus Simrén",{"id":73,"slug":4,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":86,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":46},"100645017","NCT07676136","A Pilot Study Using Gut-Directed Hypnotherapy for Hospitalized Patients","Inclusion Criteria:\n\n* Adults admitted to the GI inpatient service with expected length of stay \\>24 hours\n* Prior diagnosis of a disorder of gut-brain interaction, esophageal disorder, or inflammatory bowel disease\n* Reason for hospitalization related to symptom management for exacerbation of visceral pain and\u002For nausea.\n\nExclusion Criteria:\n\n* Currently using hypnosis\n* severe developmental delay or cognitive impairment\n* serious mental illness (i.e. psychosis or dissociation)\n* hearing impairment\n* Non-English speaking\n* enrolled in another trial for GI symptom management\n* admitted for GI procedure",{"count":78,"type":21},26,[24],"The purpose of the study is to compare the effectiveness of recorded gut-directed hypnosis to an educational recording in people with chronic problems in their gastrointestinal (GI) system. Patients who are hospitalized at Stanford Hospital for worsening pain and\u002For nausea will be considered for enrollment.",[82,83,28,84,85],"Disorders of Gut-brain Interaction","Inflammatory Bowel Disease (IBD)","Abdominal Pain","Esophageal Disease",[87],"hypnosis","2026-06-23",{"date":35,"type":38},{"date":91,"type":21},"2026-07",{"date":93,"type":21},"2028-07",{"name":95,"class":45},"Stanford University",{"id":97,"slug":4,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":124},"100632877","NCT07519395","A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)","BALANCE - A Two-part, 26-week, Randomized, Double-Blind, Dose-rAnging, pLAcebo-coNtrolled, Phase 2b Study to Evaluate the effiCacy and safEty of Camlipixant in Adults With IBS-D and IBS-M","BALANCE","Inclusion Criteria:\n\n* Male or female aged 18 to 80 years inclusive, at the time of signing the Informed consent form (ICF).\n* Diagnosis of IBS-D or IBS-M according to the Rome IV criteria at screening\n* Moderate or severe irritable bowel syndrome (IBS) based on Irritable bowel syndrome Severity Scoring System (IBS SSS) at screening visit\n* Weekly API score \\>=4.0 in each week of the run-in period\n* IBS-D: at least one stool with BSFS Type 6 or 7 consistency on at least 2 days in each week of the run-in period\n* IBS-M: an average of 2 days per week with abnormal bowel movements (BSFS Type 1, 2, 6, or 7) during the run-in period, and greater than (\\>)25% of abnormal bowel movements must be Type 6 or 7 and \\>25% Type 1 or 2\n\nExclusion Criteria:\n\n* Diagnosis of Irritable bowel syndrome - constipation (IBS-C) or Irritable bowel syndrome - unclassified (IBS-U)\n* History or presence of inflammatory or immune-mediated Gastrointestinal (GI) disorders e.g. inflammatory bowel disease, microscopic colitis, or celiac disease\n* History or presence of GI infection (confirmed with stool culture) within 3 months prior to screening\n* History or presence of bile salt diarrhea\n* History of a primary psychiatric diagnosis that the Investigator considers may interfere with study assessments (e.g., schizophrenia, schizoaffective disorder, major depression, anxiety, panic attacks or bipolar disorder) OR Hospital Anxiety and Depression Scale (HADS) score of \\>10 at screening.\n* Prior use of more than two of the following therapies or classes of therapy for the management of IBS:\n\n  * Antidepressants or neuromodulators (e.g., Tricyclic antidepressant \\[TCAs\\], Selective serotonin reuptake inhibitor \\[SSRIs\\], gabapentinoids)\n  * Antibiotics (e.g., rifaximin, neomycin)\n  * 5-hydroxytryptamine 3 (5-HT3) receptor antagonists (e.g., alosetron, ramosetron, ondansetron)\n  * Mu-opioid receptor agonists (e.g., eluxadoline)\n  * Secretagogues (e.g., linaclotide, lubiprostone, plecanatide, tenapanor)\n  * 5-hydroxytryptamine 4 (5-HT4) receptor agonists (e.g., tegaserod)\n* Abnormal thyroid function tests less than (\\\u003C) Lower limit of normal (LLN) or greater than (\\>) upper limit of normal (ULN) confirmed at screening with Thyroid stimulating hormone (TSH)\n* Positive celiac serology\n* Elevated fecal calprotectin levels\n* QT interval corrected using Fridericia's formula (QTcF) \\>450 millisecond (msec) or QTcF \\>480 msec for participants with bundle branch block using the Fridericia's corrected QT interval.\n* Clinically significant abnormal laboratory tests at screening, after one repeat laboratory test if allowed by the Medical Monitor, including the following:\n\n  * Alanine aminotransferase (ALT) \\>2\\*ULN\n  * Total Bilirubin \\>1.5\\*ULN\n  * Aspartate aminotransferase (AST) \\>2\\*ULN\n* Current or chronic history of liver disease (Child-Pugh class A, B, or C) or biliary abnormalities (with the exception of asymptomatic gallstones). Participants with known or suspected Gilbert's Syndrome are not permissible.","80 Years",{"count":105,"type":21},420,[107],"PHASE2","This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts. After the first part, some participants will be randomly chosen again to either get a higher dose or stop the drug.",[28],[111,112,113,114],"Camlipixant","Irritable bowel syndrome - Mixed","Irritable bowel syndrome - Diarrhea","Dose Ranging",{"date":116,"type":38},"2026-06-25",{"date":118,"type":38},"2026-04-08",{"date":120,"type":21},"2027-07-13",{"name":122,"class":123},"GlaxoSmithKline","INDUSTRY",110,{"id":126,"slug":4,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":46},"100630999","NCT07494968","Defining Objective Markers of Compliance for Dietary Therapies in IBS","Defining Objective Markers of Compliance for Dietary Therapies in Irritable Bowel Syndrome (IBS) Using a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients with IBS ( including diarrhea, mixed or constipation type) and without unexplained alarm features (rectal bleeding, weight loss, nocturnal pain, nocturnal diarrhea). In presence of alarm symptoms, if they have had evaluation with colonoscopy or fecal calprotectin or serum C-reactive protein (CRP) since onset of alarm symptoms with normal results, they will be included.\n2. Aged 18-65 years at the time of screening\n3. IBS-SSS of at least 175 at baseline\n\nExclusion Criteria:\n\n1. Subjects adhering to a dietary treatment such as the low-fat diet, low FODMAP diet, or gluten-free diet, within the past 6 months. Those who are lactose intolerant will not be excluded from the study and will be allowed to limit lactose intake as previously.\n2. Subjects who are predicted to make changes to their baseline IBS medication(s), over-the-counter (OTC) therapy, exercise, diet (beyond what is advised), or initiate\u002Fmake changes to other complementary therapy that could affect IBS symptoms (e.g. yoga, acupuncture, etc.) during the four weeks study period.\n3. Subjects with a known history of celiac disease, inflammatory bowel disease or microscopic colitis\n4. Subjects with a history of an eating disorder requiring medical or behavioral treatment within the past 10 years.\n5. BMI \\\u003C 18.5\n6. Subjects with prior small bowel or colonic surgery (other than appendectomy or cholecystectomy).\n7. History of appendectomy or cholecystectomy in the last 6 months.\n8. Oral antibiotic use in the past 3 months\n9. Any planned significant changes in dietary or exercise regimen within 30 days prior to Screening or during the study.\n10. Currently pregnant or breastfeeding.","65 Years",{"count":133,"type":21},94,[24],"This research will investigate if a specific marker in your stool or urine can be used to track changes in your carbohydrate intake including fructo-oligosaccharide and mannitol intake",[28],"2026-06-18",{"date":139,"type":38},"2026-06-22",{"date":141,"type":38},"2026-05-11",{"date":143,"type":21},"2027-12",{"name":145,"class":45},"University of Michigan",{"id":147,"slug":4,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":46},"100582653","NCT06866106","Well-being in IBS: Strengths and Happiness (WISH) 2.0","The WISH Intervention for IBS: Feasibility, Preliminary Effects, and Candidate Gut-Brain Mechanisms","Inclusion Criteria:\n\n* IBS Diagnosis: Adult patients with an IBS diagnosis meeting standardized Rome IV diagnostic criteria.\n* Language and communication: English fluency and access to a phone.\n\nExclusion Criteria:\n\n* Presence of inflammatory bowel disease or other structural\u002Fbiochemical primary gastrointestinal illness that better explains IBS-like symptoms: As reported by the patient, their physician, and\u002For documented in the medical record.\n* Severe psychiatric illness: Current manic episode, psychosis, or active substance use disorder diagnosed via the Mini International Neuropsychiatric Interview (MINI) or Diagnostic Interview for Anxiety, Mood, and OCD and Related Neuropsychiatric Disorders (DIAMOND).\n* Cognitive impairment: Assessed using a six-item cognitive screen developed for research.\n* Presence of atrial fibrillation or a cardiac pacemaker, or daily use of beta blocking medication: As reported by the patient and\u002For documented in the medical record.\n* Plans to start or participate in another new behavioral health intervention or psychotherapy during the study period.",{"count":153,"type":21},50,[24],"The purpose of this study is to examine the feasibility, acceptability, preliminary effects, and candidate gut-brain mechanisms of an optimized positive psychology (PP) intervention for patients with irritable bowel syndrome (IBS), entitled \"WISH,\" compared to an educational control intervention.",[28],[158,159,160,161,162],"irritable bowel syndrome","brain-gut behavior therapy","behavioral health intervention","psychological intervention","psychotherapy",{"date":139,"type":38},{"date":165,"type":38},"2025-10-30",{"date":167,"type":21},"2028-08",{"name":169,"class":45},"Massachusetts General Hospital",{"id":171,"slug":4,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":176,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":186,"leadSponsor":188,"locationsCount":46},"100513964","NCT05972317","The Stool Microbiome of Treated and Untreated IBS (Irritable Bowel Syndrome) Patients","Generating a Stool Microbiome-based Diagnostic for IBS (Irritable Bowel Syndrome) Patients in Low-FODMAP Treated and Untreated IBS Patients","Inclusion Criteria:\n\n* Male and Female\n* Age - 18-70\n\nExclusion Criteria:\n\n* Consumption of antibiotics 2 months prior to the first day of the experiment.\n* Consumption of probiotic supplements 1 month prior to the first day of the experiment.\n* Type 1 or type 2 diabetes diagnosis.\n* Pregnancy, fertility treatments, breastfeeding 3 months prior to the first day of the study.\n* Chronic disease - to the discretion of the study doctor.\n* Cancer and recent anticancer treatment.\n* Psychiatric disorders - to the discretion of the study doctor.\n* IBD (inflammatory bowel diseases).\n* Alcohol or substance abuse.\n* BMI \\> 35.",true,{"count":178,"type":21},100,[24],"Irritable bowel syndrome (IBS) is considered the most common gastrointestinal disorder in humans, with an estimated global prevalence of 11%-20% of all humans. Alterations in the gut microbiome are at the center of IBS, and microbiome-induced volatile metabolites in response to dietary exposures is believed to drive a downstream impact on susceptible hosts, thereby driving the disease. However, the characteristics and functions of these metabolites remain unknown to date. The two main mechanisms invoking IBS development and flares include 1) an increase in luminal water content due to malabsorption of small molecules and 2) incrementation of colon gas production generated by the fermentation of small molecules by gut bacteria.Yet to date, a person-specific elucidation of the specific small molecules and bacteria driving IBS, and their downstream effects on the human gut epithelium remain unknown.\n\nOver the past years, it became evident that dietary regimes, and their interactions with the intestinal microbiome, are at the center of IBS symptom generation and alleviation. The most widely used dietary intervention is a highly restrictive diet, the low-Fermentable Oligo-saccharides Di-saccharides Mono-saccharides And Polyols (FODMAP) diet, based on avoidance of multiple food items that contain available fermentable molecules.\n\nThe low-FODMAP diet remains an effective line of treatment for IBS patients, yet due to its complexity and unhealthy nature, it remains a last line of treatment and fails to impact the majority of IBS patients.",[28],"2026-06-09",{"date":184,"type":38},"2026-06-11",{"date":141,"type":38},{"date":187,"type":21},"2029-11",{"name":189,"class":45},"Weizmann Institute of Science",{"id":191,"slug":4,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":197,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":46},"100565269","NCT06639984","Psyllium in Pediatric IBS","Assessing Psyllium Given With Meals for Fructan Sensitivity in Children With Irritable Bowel Syndrome","Psyllium","Inclusion Criteria:\n\n* Children between the ages of 12-17 years meeting pediatric Rome IV criteria for IBS\n\nExclusion Criteria:\n\n* Children who have had previous bowel surgery, have documented GI disorders (e.g., ulcerative colitis), or a serious chronic medical condition (e.g., diabetes)\n* weight and\u002For height are \\> or \\< 2 SD for age\n* have chronic conditions with GI symptoms (e.g., cystic fibrosis)\n* have been on antibiotics or probiotics within 3 months (because of potential alterations to the GI microbiome0\n* girls who are pregnant (tested with urine beta-human chorionic gonadotropin at the initial visit)","12 Years","17 Years",{"count":124,"type":21},[107],"The goal of this clinical trial is to learn if a fiber (psyllium) can change the way bacteria use fructans (a type of sugar) and whether psyllium can help decrease childhood irritable bowel syndrome (IBS) symptoms when eating fructans. The main questions it aims to answer are:\n\nAim 1: The effect of psyllium at two doses given with a fructan meal on microbial fructan fermentation (intracolonic pH; H2 gas production; gut microbiome composition; fecal short-chain fatty acids, lactate, glycomics).\n\nAim 2: Determine the impact of psyllium given with a fructan meal on fructan-induced GI symptoms.\n\nParticipants will first be asked to eat a specific diet over two three-day periods to determine if fructans worsen their IBS symptoms. Those with worsening symptoms with fructans will be asked to participate in the second part of the study. This includes two weeks of baseline (no change in diet) and two weeks of eating a specific diet with fructans with either psyllium or glucose. Participants will be asked to complete pain and stool diaries, submit stool specimens, swallow a pill to capture gut acid levels, and give breath samples.",[28],[84],"2026-05-21",{"date":206,"type":38},"2026-05-26",{"date":208,"type":38},"2025-02-20",{"date":210,"type":21},"2027-09-30",{"name":212,"class":45},"Dr Bruno Chumpitazi, M.D.",{"id":214,"slug":4,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":229,"leadSponsor":231,"locationsCount":46},"100638973","NCT07600047","A Well-Being Intervention for People With IBS","Inclusion Criteria:\n\n* Men and women currently diagnosed with Irritable Bowel Syndrome (IBS) by a healthcare provider.\n* Able to read and write in English.\n* Willing to complete questionnaires and participate in either the intervention or control group.\n* Capable of providing informed consent.\n* Must be a UW Health patient or referred through UW Digestive Health Center.\n\nExclusion Criteria:\n\n* Individuals with cognitive impairments or reading difficulties that would interfere with understanding study materials or completing assessments.\n* Individuals unable to provide informed consent.\n* Prior participation in a similar intervention study.\n* Non-English speakers (since study materials are in English)",{"count":219,"type":21},150,[24],"The purpose of this randomized behavioral clinical trial is to examine whether a well-being intervention can improve both psychological well-being and physical outcomes in adults with Irritable Bowel Syndrome (IBS). The study aims to assess whether this intervention decreases anger, anxiety, and depression; increases self-esteem, empathy, and hope; and improves quality of life indicators such as IBS symptom severity, sleep quality, fatigue, and diet. Participants can expect to be on study for up to 9 months.",[28],[224],"well being","2026-05-19",{"date":227,"type":38},"2026-05-22",{"date":40,"type":21},{"date":230,"type":21},"2027-08",{"name":232,"class":45},"University of Wisconsin, Madison",{"id":234,"slug":4,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":255},"100634905","NCT07545759","A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-D","RENEW-IBS-D","Inclusion Criteria:\n\n* Meet Rome IV criteria for IBS-D, which includes having greater than 25% of bowel movements with Bristol Stool Form Scale (BSFS) Types 6 or 7 and \\\u003C25% of bowel movements with BSFS Types 1 or 2\n* Based on the daily eDiary collection during the screening period:\n\n  * Have average of worst abdominal pain score of ≥3.0 on a 0-to-10-point scale during the 14 consecutive days prior to randomization\n  * Have at least 4 days per week with a maximum BSFS ≥5 AND with at least 2 days of the 4 days per week with a maximum BSFS ≥6 during the 14 consecutive days prior to randomization\n* Have had no major changes in diet in the 4 weeks prior to screening\n\nExclusion Criteria:\n\n* Have a diagnosis of IBS with a subtype of constipation, mixed IBS, or unclassified IBS by the Rome IV criteria\n* Have a history of inflammatory or immune-mediated gastrointestinal disorders\n* Have a known clinically significant gastric emptying abnormality","75 Years",{"count":242,"type":21},531,[107],"The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo.\n\nThe study will last approximately 35 weeks.",[28,246],"Diarrhea",{"date":248,"type":38},"2026-05-13",{"date":250,"type":38},"2026-05-06",{"date":252,"type":21},"2027-11",{"name":254,"class":123},"Eli Lilly and Company",88,{"id":257,"slug":4,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":240,"enrollmentInfo":263,"targetDuration":4,"studyType":22,"phases":265,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":269,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":46},"100634906","NCT07545772","A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-C","RENEW-IBS-C","Inclusion Criteria:\n\n* Meets Rome IV criteria for irritable bowel syndrome-constipation (IBS-C) including having more than 25% bowel movements with Bristol Stool Form Scale (BSFS) Types 1 or 2 and less than 25% of bowel movements with BSFS Types 6 or 7\n* Based on the daily eDiary collection during the screening period:\n\n  * Have average of worst abdominal pain score of ≥3.0 on a 0-to-10-point scale during the 14 consecutive days prior to randomization\n\nExclusion Criteria:\n\n* Have a diagnosis of irritable bowel syndrome (IBS) with a subtype of diarrhea, mixed IBS, or unclassified IBS by the Rome IV criteria\n* Have a history of inflammatory or immune-mediated gastrointestinal disorders\n* Have a known clinically significant gastric emptying abnormality",{"count":264,"type":21},342,[107],"The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo.\n\nThe study will last approximately 35 weeks.",[28,268],"Constipation",{"date":248,"type":38},{"date":271,"type":38},"2026-04-29",{"date":273,"type":21},"2027-09",{"name":254,"class":123},{"id":276,"slug":4,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":22,"phases":283,"briefSummary":285,"conditions":286,"keywords":294,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":303,"locationsCount":46},"100536954","NCT06271538","Evaluation of Efficacy of Skål Pro Powder on Symptoms of Irritable Bowel Syndrome","A Randomized Double-Blind Placebo-controlled Clinical Trial on the Efficacy of Skål Pro (Lactobacillus Plantarum 299 and Galacto-oligosaccharides) in Improving Severity of Symptoms, Stool Forms, Quality of Life and Psychological Dysfunction in Patients With Irritable Bowel Syndrome (IBS)","Inclusion Criteria:\n\n* IBS diagnosed using the Rome IV criteria\n* Age above 18 years old and any gender\n* Any subtypes of IBS (diarrhea, constipation or mixed)\n\nExclusion Criteria:\n\n* Presence of red flag symptoms (weight loss, anemia, night symptoms, abdominal mass, strong family history of cancer)\n* Was prescribed antibiotic (s) within the past one month\n* Medical conditions that contraindicate probiotic use including severe sepsis and pregnancy\n* Presence of bowel malignancy\n* Diagnosis of bowel infection within the past one month\n* Previous abdominal surgeries\n* Patients with overt psychiatric illnesses including schizophrenia and manic disorders\n* A history of allergy to probiotic\n* Was prescribed probiotic (s) within the past one month\n* Was previously prescribed probiotic Skal Pro™ (LP299V™)",{"count":282,"type":21},60,[284],"PHASE4","The objective of this randomized, double-blind, placebo-controlled study is to evaluate the effectiveness of Skal Pro in alleviating symptoms, enhancing stool consistency, improving quality of life, and addressing psychological distress in individuals diagnosed with irritable bowel syndrome (IBS), as compared to those who receive no intervention.",[28,287,288,289,290,291,292,293],"Gastrointestinal Diseases","Colonic Diseases, Functional","Intestinal Disease","Digestive System Disease","Pathologic Processes","Colonic Disease","Disease",[295,296,297],"probiotic","Lactobacillus plantarum 299v","randomized controlled study",{"date":299,"type":38},"2026-05-12",{"date":301,"type":38},"2024-10-17",{"date":35,"type":21},{"name":304,"class":123},"EP Plus Group Sdn Bhd",{"id":306,"slug":4,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":312,"targetDuration":4,"studyType":22,"phases":314,"briefSummary":315,"conditions":316,"keywords":321,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":46},"100639308","NCT07581756","Repeated Transcranial Magnetic Stimulation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial","Repeated Transcranial Magnetic Stimulation (rTMS) for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Clinical Trial","rTMS","Inclusion Criteria:\n\nEligible participants had to be between 18- 60 years of age and fulfill the Rome IV criteria for IBS-D. Specifically, patients must have experienced recurrent abdominal pain at least one day per week in the last three months, with symptom onset at least six months prior to diagnosis, associated with defecation or a change in the frequency or form (appearance) of stool. More than 25% of stool episodes be classified as Bristol Stool Form Scale (BSFS) type 6 or 7, and fewer than 25% as type 1 or 2. In addition, patients were required to exhibit moderate to severe symptoms, defined as an Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) score greater than 175 (on a 500-point scale). Dietary preferences of all participants included non vegetarian options and participants maintain stable dietary habits for at least one month prior to randomization. Moreover, patients aged over 50 were required to provide documentation of a normal colonoscopy performed within the preceding three years.\n\nExclusion Criteria:\n\nThe exclusion criteria included a completion rate of daily diaries of less than 50% during the screening period, a history of organic gastrointestinal disease, such as inflammatory bowel disease, a history of surgical resection of the GI tract or cholecystectomy, a recent diagnosis of Helicobacter pylori infection within the past 2 years, a history of gluten or lactose intolerance, a history of malignancy, or a history of neurological or psychiatric conditions. Additionally, individuals with severe systemic diseases, including uncontrolled diabetes mellitus, hyperthyroidism, or severe hepatic, renal, or cardiac insufficiency, were excluded. The use of probiotic or prebiotic supplements, antibiotics (including rifaximin), prokinetic or antidiarrheal agents, tricyclic antidepressants, or immunosuppressive therapies was not permitted within 4 wk prior to screening. Prohibited conditions during the study period included pregnancy, lactation, or being within 12 months postpartum. Lastly, participants with severe needle phobia, metal allergies, implanted cardiac pacemakers, or a known allergic diathesis were excluded. All participants provided their voluntary, written, informed consent prior to their inclusion.",{"count":313,"type":21},46,[24],"Objectives: This study aims to evaluate the clinical efficacy and safety of repetitive transcranial magnetic stimulation (rTMS) in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), and to explore the potential underlying mechanisms by which rTMS alleviates clinical symptoms in IBS-D patients.\n\nDesign: This is a clinical trial that uses clinical symptom scales to assess the therapeutic effect of rTMS on IBS-D patients. Meanwhile, gut microbiota and metabolite profiling, as well as the methane-hydrogen breath test, will be applied to investigate the mechanism of action from the perspectives of gut microecology, intestinal motility, and metabolism, so as to provide scientific evidence for the clinical application of rTMS in the treatment of IBS-D.",[28,317,318,319,320],"Irritable Bowel Syndrome With Diarrhea (IBS-D)","Repetitive Transcranial Magnetic Stimulation (rTMS)","Chronic Diarrhea","Intestinal Flora",[322,318],"Irritable Bowel Syndrome with diarrhea (IBS-D)",{"date":299,"type":38},{"date":325,"type":38},"2024-12-01",{"date":327,"type":21},"2026-07-01",{"name":329,"class":45},"The First Affiliated Hospital of Soochow University",{"id":331,"slug":4,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":336,"minAge":17,"maxAge":52,"enrollmentInfo":337,"targetDuration":4,"studyType":22,"phases":339,"briefSummary":340,"conditions":341,"keywords":342,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":46},"100498950","NCT05776914","Fecal Microbiota Transplantation for IBS","Efficacy and Safety of Proteolytic Activity-Guided Fecal Microbiota Transplantation for Irritable Bowel Syndrome (PRAGMAT Trial)","Inclusion Criteria:\n\n* IBS defined by Rome IV criteria\n* Non IBS-C\n* Moderate to severe symptoms defined by IBS-SSS≥175\n* Able to safely undergo and consent to colonoscopy\n\nExclusion Criteria\n\n* Immune deficiency or treatment with immunosuppressive medications\n* Severe bowel or medical disease precluding administration of bowel prep\n* Severe bowel or medical disease precluding colonoscopy with conscious sedation\n* Active cancer\n* Pregnant or lactating\n* Abdominal surgery (exception of splenectomy, partial hepatectomy, partial\u002Funilateral nephrectomy, laparoscopy, pelvic floor repair, mesh, liposuction, fundoplication, tubal ligation, gastric sleeve, oophorectomy, hernia, appendectomy, cholecystectomy, caesarean section and hysterectomy)\n* Severe psychiatric disorder (HADS-A or D\\>16), or diagnosed alcohol or drug abuse disorder\n* New probiotics or treatment with antibiotics, NSAIDs (within 4 wks prior to study entry)\n* Use of treatments known to affect colonic motility (with exception of loperamide)\n* Diagnosed h\u002Fo bleeding disorder\n* Organic GI diseases (IBD, celiac disease, microscopic colitis)\n* Chronic kidney or liver disease\n* Absolute neutrophil count (ANC) \\\u003C500 IU\u002Fml","FEMALE",{"count":338,"type":21},43,[107],"The purpose of this study is to learn the efficacy and safety of fecal microbiota transplantation (FMT) using stool from a donor with low proteolytic activity and containing the bacteria Alistipes putredinis in patients with irritable bowel syndrome (IBS) and high proteolytic activity. Proteolytic activity is the breakdown of proteins into smaller polypeptides or amino acids.",[28,246],[343,344],"Post-infection irritable bowel syndrome with diarrheal","Post-infection irritable bowel syndrome with mixed symptoms",{"date":346,"type":38},"2026-05-08",{"date":348,"type":38},"2024-04-15",{"date":350,"type":21},"2027-06-26",{"name":352,"class":45},"Madhusudan (Madhu) Grover, MBBS",{"id":354,"slug":4,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":336,"minAge":358,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":22,"phases":362,"briefSummary":363,"conditions":364,"keywords":365,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":372,"locationsCount":46},"100636027","NCT07560345","Effect of Neurodynamic Mobilization of Vagus Nerve on Irritable Bowel Syndrome in Women","Inclusion Criteria:\n\n* 32 Females with mild to moderate IBS ,were recruited for this study by referral from a physician.\n* aged 20-45 (i.e., the most common age for developing IBS)\n* Patients must experience abdominal pain recurring at least once weekly over the past three months.\n* This pain must be linked to two or more of the following features: occurring in relation to defecation, accompanied by a change in stool frequency, or accompanied by a change in stool form or appearance.\n* Symptoms should have been present during the last three months, with onset at least six months before diagnosis.\n\nExclusion Criteria:\n\nSubjects will be excluded if they have:\n\n* Organic gastrointestinal disorders.\n* Thyroid abnormalities.\n* Coexisting cardiovascular, respiratory, renal, or hepatic conditions.\n* Pregnancy.\n* Blood disorders. (e.g., hemophilia, coagulation disorders, leukemia, thalassemia, sickle cell disease).\n* Neurological or musculoskeletal conditions affecting muscle tone.\n* Psychiatric illnesses ( patients with depression in the absence of IBS).\n* Fibromyalgia.\n* A history of gastrointestinal surgery or resection, , or other chronic diseases associated with gastrointestinal issues such as inflammatory bowel disease, ulcers, or cancer.\n* A history of alcohol or drug abuse, abdominal surgery within the past six months.\n* Recent cervical or cardiac surgery, or recent major trauma.","20 Years","45 Years",{"count":361,"type":21},32,[24],"goal of this interventional study to investigate the effect of neurodynamic mobilization of vagus nerve on irritable bowel syndrome in women. The main question it aims to answer is: is there an effect of neurodynamic mobilization of the vagus nerve on irritable bowel syndrome? The intervention will include neurodynamic mobilization of vagus nerve sessions ,Participants will receive the treatment for 6 week. Assessment will be done before and after treatment.",[28],[158],"2026-05-02",{"date":368,"type":38},"2026-05-07",{"date":370,"type":21},"2026-05-01",{"date":91,"type":21},{"name":373,"class":45},"Cairo University",{"id":375,"slug":4,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":379,"enrollmentInfo":380,"targetDuration":4,"studyType":22,"phases":381,"briefSummary":382,"conditions":383,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":46},"100491564","NCT05680766","Feasibility Assessment of Cardiovascular Endurance Training for the Symptomatic Improvement of Irritable Bowel Syndrome Patients With a Sedentary and Non-active Lifestyle.","Inclusion Criteria:\n\n* Patients aged 18 - 60 years;\n* Fulfilling the ROME IV criteria for Irritable bowel syndrome (IBS);\n* Moderate symptom severity as defined by a IBS-Symptom Severity Scale \\> 175;\n* Sedentary lifestyle defined as SIT-Q-7D \\> 8h\u002Fday;\n* Physically inactive defined as \\\u003C 150min\u002Fweek on the IPAQ score\n\nExclusion Criteria:\n\n* Cardiorespiratory disorder hampering participation in a program of physical exercise as evidenced by the sport + keuringsartsen (SKA) questionnaire.\n* Clinical suspicion of an organic disorder different from IBS (patients can be included when this disorder had been excluded);\n* Known inflammatory bowel disorder;\n* Known intestinal motility disorder;\n* Alcohol (defined as more than 14 U per week) or other substance abuse;\n* Active psychiatric disorder;\n* Known systemic or auto-immune disorder with implication for the GI system;\n* Prior abdominal surgery (with the exception of appendectomy or cholecystectomy more than 6 months ago);\n* Any prior diagnosis of cancer other than basocellular carcinoma;\n* Current chemotherapy;\n* History of gastro-enteritis in the past 8 weeks;\n* Change in diet in the past 8 weeks;\n* Dietary supplements unless taken at a stable dose for more than 8 weeks;\n* Antibiotics, pre-, pro-, post-biotics or any combination during the past 8 weeks;\n* Treatment with neuromodulators (one neuromodulator taken at a stable dose for more than 12 weeks is allowed);\n* Treatment with spasmolytic agents, opioids, loperamide, gelatine tannate or mucoprotect-ants during the past 8 weeks.","60 Years",{"count":20,"type":21},[24],"This exploratory study's primary objective is the changes of irritable bowel syndrome (IBS) symptom severity by cardiovascular endurance training (CET) in relation to the baseline sedentary or non-active lifestyle. Secondary endpoints focus on the mechanisms associated with these changes.\n\nThese mechanisms relate to dietary adaptations, changes in anxiety, depressive comorbidity, somatisation, alterations in the gut microbiome or metabolome, body composition and measures of cardiovascular fitness. Virtually all IBS guidelines mention lifestyle modifications as a management option.\n\nResearch on the role of physical activity remains underassessed as compared to the other interventions. Therefore, an exploratory proof-of-concept study will investigate the influence of regular physical exercise on symptoms in a small group of IBS patients. This study will gather data on putative underlying mechanisms related to dietary factors, faecal microbiome and metabolome, mental well-being, body composition and cardiovascular fitness.",[28],"2026-04-30",{"date":250,"type":38},{"date":387,"type":38},"2023-10-16",{"date":389,"type":21},"2030-01-02",{"name":391,"class":45},"Universitair Ziekenhuis Brussel",{"id":393,"slug":4,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":399,"phases":4,"briefSummary":400,"conditions":401,"keywords":403,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":420,"leadSponsor":422,"locationsCount":46},"100634389","NCT07539051","Psychoemotional Status and Functional Gastrointestinal Disorders","Assessment of the Influence of Psychoemotional Status on the Clinical Course of Functional Disorders of the Stomach and Intestine","Inclusion Criteria:\n\n* Age 18 years and older\n* Diagnosis of irritable bowel syndrome and\u002For functional dyspepsia according to Rome IV criteria\n* Written informed consent for participation in the study\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Clinical presentation not meeting Rome IV criteria\n* Inflammatory bowel disease\n* Pregnancy or lactation\n* Malignant neoplasms of any localization\n* History of gastrointestinal surgery",{"count":219,"type":21},"OBSERVATIONAL","This prospective cohort study will evaluate the influence of psychoemotional status on the clinical course and quality of life of adult patients with functional dyspepsia and\u002For irritable bowel syndrome diagnosed according to Rome IV criteria. The study aims to assess the contribution of affective and somatoform disorders to quality of life and symptom burden in these patients. In participants with functional dyspepsia, the association of Helicobacter pylori status with psychoemotional status and quality of life will also be evaluated. Patients will complete validated questionnaires assessing quality of life, depression, anxiety, and somatization at baseline and again during follow-up after treatment. Clinical symptoms, pain severity, stool characteristics, and H. pylori status will also be assessed as applicable.",[402,28],"Functional Dyspepsia",[404,405,406,407,408,409,410,411,412,413,414,415],"Psychoemotional Status","Quality of Life","Anxiety","Depression","Somatization","PHQ-9","GAD-7","PHQ-15","SF-36","Helicobacter pylori","Rome IV","Gut-Brain Interaction","2026-04-13",{"date":418,"type":38},"2026-04-20",{"date":370,"type":21},{"date":421,"type":21},"2028-05-01",{"name":423,"class":45},"Center of New Medical Technologies",{"id":425,"slug":4,"hasResults":11,"nctId":426,"briefTitle":427,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":336,"minAge":358,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":22,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":439,"leadSponsor":441,"locationsCount":46},"100633962","NCT07533500","Effect of Autogenic Relaxation Training on Irritable Bowel Syndrome In Adult Females","Inclusion Criteria:\n\n* Patients diagnosed with irritable bowel syndrome (IBS) based on Rome IV diagnostic criteria constipation- predominant IBS.\n\nTheir body mass index 25- 30.\n\nExclusion Criteria:\n\n* Organic gastrointestinal disorder, thyroid dysfunction, respiratory, renal, hepatic disorder.\n* Pregnancy, hematological disease, neurological and psychiatric disease.\n* Previous history of stomach or intestinal excision.","35 Years",{"count":431,"type":21},44,[24],"This study will be conducted to determine the effect of autogenic relaxation training on irritable bowel syndrome in adult females.",[28],"2026-04-10",{"date":437,"type":38},"2026-04-16",{"date":418,"type":21},{"date":440,"type":21},"2026-09-10",{"name":373,"class":45},{"id":443,"slug":4,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":449,"enrollmentInfo":450,"targetDuration":4,"studyType":22,"phases":451,"briefSummary":452,"conditions":453,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":46},"100581211","NCT06847360","Home-based Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for IBS Pain","Home-Based Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Pain and Symptom Management Among Young Adults With Irritable Bowel Syndrome (IBS)","IBS-taVNS","Inclusion Criteria:\n\n* 18 - 29 years of age;\n* Men and women;\n* Diagnosis of IBS from a healthcare provider with current report of pain (volunteers asked to bring provider-verification of IBS diagnosis based on Rome IV criteria to initial study appointment);\n* Experiencing moderate pain (≥3 out of 10 on numeric rating scale \\[NRS\\]) at least 4 days of the week and lasting previous three months;\n* Daily access to a computer connected to the internet; and\n* Able to read and speak English.\n\nExclusion Criteria:\n\n* Other chronic pain condition;\n* Celiac disease or inflammatory bowel disease;\n* Diabetes mellitus;\n* severe psychiatric condition requiring inpatient treatment in previous 6 months;\n* Pregnancy or lactation;\n* Regular use of opioids or other illicit substances;\n* use of probiotics or antibiotics within 2 weeks from enrollment; and\n* any other conditions\u002Fcontraindications that prohibit the application of taVNS including but not limited to any current or past history of cardiovascular disorders, recent ear trauma, and metal implants above the level of the neck.","29 Years",{"count":5,"type":21},[24],"The goal of this clinical trial is to learn the feasibility and safety of using home-based taVNS in young adults with IBS to manage their IBS-related pain and symptoms. It will also learn about participants' experience in using the home-based taVNS intervention. The main questions it aims to answer are:\n\n* Is it feasible to use a home-based taVNS intervention for pain and symptom management among YAs with IBS?\n* Is it safe and reported satisfactory to use a home-based taVNS intervention for pain and symptom management among YAs with IBS? Researchers will compare Active to Sham taVNS (a look-alike intervention that contains minimal stimulation) to see if Active taVNS works on managing IBS-related pain and symptoms.\n\nParticipants will:\n\n* Take Active or Sham taVNS intervention for a 6-week treatment (twice daily, 30 minutes per session)\n* Visit the research lab at the initial setup and the end of the 6-week treatment for checkups and tests\n* Keep a diary of their symptoms and the number of times they use the taVNS.",[454,28,455],"Pain, Chronic","Symptom Cluster","2026-04-09",{"date":416,"type":38},{"date":459,"type":38},"2026-01-19",{"date":461,"type":21},"2028-01",{"name":44,"class":45},{"id":464,"slug":4,"hasResults":11,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":469,"targetDuration":4,"studyType":22,"phases":471,"briefSummary":473,"conditions":474,"keywords":478,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":485,"locationsCount":46},"100633097","NCT07522255","Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders","The Effect of Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders: A Randomized Double-blind Placebo-Controlled Trial With Gut Microbiota and Intestinal Gas Analysis","Inclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Rome IV diagnosis of irritable bowel syndrome, functional constipation, or functional abdominal bloating\u002Fdistension.\n* Bothersome bloating with baseline severity of at least 3 on a 7-point Likert scale after adequate constipation treatment, defined as stool frequency from at least 3 times\u002Fweek to 3 times\u002Fday and Bristol Stool Form Scale type 3-5.\n* Colonoscopy, CT colonography, or barium enema performed if clinically indicated as part of standard evaluation for bowel symptoms.\n\nExclusion Criteria:\n\n* History of major gastrointestinal surgery, except appendectomy or laparoscopic cholecystectomy.\n* Inflammatory bowel disease or other inflammatory gastrointestinal conditions.\n* Current use of, or inability to discontinue, medications that may affect intestinal microbiota or gas measurements, including antibiotics, proton pump inhibitors, probiotics, lactulose, NSAIDs, or metformin.\n* Current use of, or inability to discontinue, medications that may affect bloating symptoms, including simethicone, simethicone-containing antispasmodics, or antidiarrheal medications.\n* Underlying conditions known to affect intestinal microbiota composition, including cirrhosis, uncontrolled diabetes mellitus, end-stage renal disease, obesity, malignancy, or psychiatric disorders.\n* Opioid-induced constipation.\n* Known allergy to rifaximin.",{"count":470,"type":21},78,[472],"PHASE3","This randomized, double-blind, placebo-controlled trial will evaluate whether a 14-day course of rifaximin improves bloating in adult patients with Rome IV functional bowel disorders in whom bloating is the predominant symptom. Eligible participants with irritable bowel syndrome, functional constipation, or functional abdominal bloating\u002Fdistension and bothersome bloating despite adequate bowel movement management will be assigned in a 1:1 ratio to rifaximin 550 mg three times daily or matching placebo for 2 weeks. The primary endpoint is the proportion of participants with bloating response, defined as at least a 1-point reduction from baseline in a 7-point Likert bloating score at the end of treatment.",[475,476,477,28,268],"Bloating","Rifaximin","Functional Bowel Disorder",[476,475,479],"Functional bowel disorder","2026-04-03",{"date":416,"type":38},{"date":483,"type":21},"2026-04",{"date":143,"type":21},{"name":486,"class":45},"Mahidol University",{"id":488,"slug":4,"hasResults":11,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":11,"sex":16,"minAge":494,"maxAge":131,"enrollmentInfo":495,"targetDuration":4,"studyType":22,"phases":496,"briefSummary":497,"conditions":498,"keywords":500,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":46},"100587085","NCT06923800","Exercise Interventions and Dietary Advice in Fibromyalgia and IBS","Comparison of Two Exercise Interventions and Dietary Advice in Patients With Fibromyalgia and Irritable Bowel Syndrome: A Randomized Controlled Crossover Study","FM-IBS","Inclusion Criteria:\n\n* Confirmed diagnosis of Irritable Bowel Syndrome (IBS) concomitant with Fibromyalgia (FM).Meeting the American College of Rheumatology (ACR) diagnostic criteria for FM and meeting the Rome III\u002FIV diagnostic criteria for IBS.\n* Total score on the Irritable Bowel Syndrome Severity Scoring System (IBS-SSS) ≥ 125 (indicating moderate to severe IBS symptoms).\n* Men and women aged between 30 and 65 years.\n* Body Mass Index (BMI) between 18.5 and 29.9.\n\nExclusion Criteria:\n\n* Individuals with severe cardiac, hepatic, neurological, psychiatric disorders, or other gastrointestinal diseases.\n* Individuals unable to discontinue symptom management therapies and medications for FM\u002FIBS.","30 Years",{"count":20,"type":21},[24],"Fibromyalgia (FM) is a chronic disorder marked by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive difficulties. Patients often experience hyperalgesia, allodynia, and muscle weakness. Central sensitization plays a key role, making the nervous system more responsive to pain. Though muscles are mainly affected, joint pain, stiffness, and reduced mobility are also common. Chronic pain and poor posture can worsen musculoskeletal health. FM is not mainly inflammatory, but pain and stress may affect bone health. Sleep disorders, like non-restorative sleep and apnea, are frequent and worsen fatigue. Neurotransmitter imbalances (e.g., serotonin, dopamine) affect pain and muscle function.\n\nThe American College of Rheumatology defines FM by widespread bilateral pain lasting at least three months. FM mainly affects women, with a prevalence of 0.2-6.6%, often starting between the ages of 30 and 35. Besides physical symptoms, many patients suffer from anxiety, depression, and mood disorders, affecting their quality of life.\n\nGastrointestinal issues, especially irritable bowel syndrome (IBS), are also frequent in FM patients. Both conditions share mechanisms such as pain hypersensitivity, altered autonomic regulation, gut-brain axis disruption, and immune dysfunction. Low-grade inflammation and intestinal permeability may contribute to chronic symptoms.\n\nFM treatment includes anticonvulsants, antidepressants, and painkillers. IBS is managed with diet changes and medications like antispasmodics. Due to limited drug effectiveness, multidisciplinary approaches are gaining attention. Physical exercise is a proven non-drug strategy that improves pain, fatigue, and mental health in FM and IBS. Still, adherence is low due to fear of pain, fatigue, and low motivation.\n\nExercise, especially aerobic activity, benefits IBS patients by improving gut symptoms and reducing inflammation. It may also strengthen the gut barrier in both conditions. While optimal programs need more study, exercise is a promising therapy. Major health bodies recommend aerobic, resistance, and flexibility training for FM and aerobic exercise for IBS.",[499,28],"Fibromyalgia",[501,502,503,158],"exercise","aerobic exercise","fibromyalgia","2026-03-24",{"date":506,"type":38},"2026-03-27",{"date":508,"type":38},"2025-04-14",{"date":510,"type":21},"2028-12",{"name":512,"class":45},"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis",{"id":514,"slug":4,"hasResults":11,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":520,"targetDuration":4,"studyType":22,"phases":521,"briefSummary":522,"conditions":523,"keywords":524,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":534,"locationsCount":46},"100501344","NCT05808036","Efficacy of the DOMINO Diet App in IBS","The Efficacy of the DOMINO Diet Application Versus the Low FODMAP Diet in Tertiary Care IBS Patients","EDDI","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.\n3. Patients with irritable bowel syndrome according to Rome IV diagnostic criteria\n4. Patients ages between 18 and 70 years old\n\nExclusion Criteria:\n\n1. Participant has a history of any major psychiatric disorders (including those with a major psychosomatic element to their gastrointestinal disease), depression, alcohol or substance abuse in the last 2 years\n2. Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol\n3. Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial\n4. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive\n5. Participation in an interventional Trial with an investigational medicinal product (IMP) or device\n6. Patients presenting with predominant symptoms of functional dyspepsia (FD) and of gastro-oesophageal reflux disease (GERD)\n7. Patients following a diet interfering with the study diet in opinion of the investigator\n8. Patients who already followed the low FODMAP diet under guidance of a trained dietitian without success",{"count":124,"type":21},[24],"The aim of this study is to evaluate whether the DOMINO diet application is an effective tool in the treatment of Irritable bowel syndrome in tertiary care. Furthermore, this study aims to determine the response rate of the strict low FODMAP diet in non-responders to the DOMINO diet.",[28],[525,526,527],"DOMINO","Low FODMAP diet","Irritable bowel syndrome","2026-03-18",{"date":530,"type":38},"2026-03-19",{"date":532,"type":38},"2023-04-01",{"date":40,"type":21},{"name":535,"class":45},"Universitaire Ziekenhuizen KU Leuven",{"id":537,"slug":4,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":176,"sex":16,"minAge":17,"maxAge":131,"enrollmentInfo":542,"targetDuration":4,"studyType":22,"phases":544,"briefSummary":545,"conditions":546,"keywords":547,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":4},"100628871","NCT07467278","Low-FODMAP Diet and Intestinal Permeability in Patients With Irritable Bowel Syndrome","The Effect of Low-FODMAP Diet on Leaky Gut ,Symptoms and Quality of Life in Patient With Irritable Bowel Syndrome","Inclusion Criteria:Age between 18 and 65 years\n\nDiagnosis of Irritable Bowel Syndrome (IBS) according to Rome IV criteria\n\nPatients presenting to Internal Medicine or Gastroenterology outpatient clinics\n\nAbility to provide written informed consent\n\nWillingness to comply with the assigned dietary intervention and follow-up schedule\n\nPatients who were mostly compliant or fully compliant with the dietary protocol (≥51%)\n\n\\-\n\nExclusion Criteria:\n\n* IBS-specific treatment within the last 1 month\n\nAntibiotic or probiotic use within the previous 2 weeks\n\nHistory of major abdominal surgery\n\nActive malignancy\n\nHeart failure\n\nRenal failure\n\nAutoimmune disease\n\nInflammatory bowel disease\n\nCeliac disease\n\nLactose intolerance\n\nIndividuals currently following another dietary regimen\n\nPregnancy\n\nPoor adherence to diet protocol (\\\u003C51%)\n\nFailure to submit dietary diaries regularly\n\nNeed for antibiotic therapy during the intervention period",{"count":543,"type":21},24,[24],"This study aimed to evaluate the effects of a Low-FODMAP diet on intestinal permeability, symptom severity, and quality of life in patients with Irritable Bowel Syndrome (IBS). Twenty-four patients diagnosed with IBS according to the Rome IV criteria were randomized to either a Low-FODMAP diet or a traditional diet for four weeks. Stool zonulin family peptides (ZFP), IBS Symptom Severity Score (IBS-SSS), and IBS Quality of Life (IBS-QOL) questionnaires were recorded at baseline and after the dietary intervention. In the Low-FODMAP group, FODMAP-containing foods were gradually reintroduced under dietitian supervision, and assessments were repeated at week 16 to evaluate long-term effects.",[28],[548],"IBS,FODMAP DIET,ZONULIN","2026-03-09",{"date":551,"type":38},"2026-03-12",{"date":553,"type":21},"2026-03-15",{"date":555,"type":21},"2026-08-30",{"name":557,"class":45},"Istanbul Medipol University Hospital",{"id":559,"slug":4,"hasResults":11,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":176,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":563,"targetDuration":4,"studyType":22,"phases":565,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":46},"100496137","NCT05740319","Efficacy and Safety Evaluation of Fecal Microbiota Transplantation in Irritable Bowel Syndrome","Inclusion Criteria:\n\n* Patients who fulfilled the Rome IV criteria for the diagnosis of IBS, aged 18-70 years;\n* Patients who have experienced failure of at least 3 conventional therapies for IBS;\n* Absence of red flags such as weight loss, hematochezia;\n\nExclusion Criteria:\n\n* Pregnant, planning pregnancy or lactating;\n* Psychiatric disorder or unable to cooperate with treatment and follow-up visit;\n* Immunodeficiency or treatment with immune-modulating medication;\n* Use of probiotics within the previous 3 months or treatment with antibiotics within 1 month prior to study entry;\n* Having undergone any abdominal surgery, with the exception of appendectomy, cholecystectomy, caesarean section and hysterectomy;\n* Presence of uncontrolled diabetes, hypertension, thyroid disease or other systemic disease;\n* Presence of severe diseases related to heart, brain, kidney and lung or concomitant malignancies;",{"count":564,"type":21},102,[24],"Participants will be given FMT through oral capsules or nasojejunal tube once a month. After three-time treatment, participants were followed up for three months. Participants complete specific scales to assess improvement in symptoms, emotion and quality of life. Besides, they report adverse effects and collect fecal samples at each visit.",[28],"2026-02-24",{"date":570,"type":38},"2026-02-25",{"date":572,"type":38},"2023-06-10",{"date":574,"type":21},"2026-12-31",{"name":576,"class":45},"Shanghai Zhongshan Hospital",{"id":578,"slug":4,"hasResults":11,"nctId":579,"briefTitle":580,"officialTitle":580,"acronym":581,"eligibilityCriteria":582,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":240,"enrollmentInfo":583,"targetDuration":4,"studyType":22,"phases":584,"briefSummary":585,"conditions":586,"keywords":587,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":46},"100595999","NCT07039747","Effectiveness of a Dietary Supplement in Irritable Bowel Syndrome","ACALMI","Inclusion Criteria:\n\n* Irritable bowel syndrome according to Rome IV criteria\n* Aged between 18 and 75 years\n* IBS-SSS \\> 175 at inclusion\n* For women of childbearing age, use of effective contraception (progestins or oestroprogestins or intrauterine device or tubal ligation) for 1 month unless postmenopausal (amenorrhoea of at least 12 months or biologically confirmed diagnosis) or woman who has had a hysterectomy or salpingectomy.\n* Irritable bowel syndrome treatments that have been stable for more than one month\n* Membership of a social security scheme\n* Patient has read and understood the information letter and signed the consent form\n\nExclusion Criteria:\n\n* Taking probiotics, food supplements containing glutamine, anti-inflammatory drugs or antibiotics in the month preceding the study.\n* Allergy to fish and glutamine\n* Known renal insufficiency (Glomerular Filtration Rate (GFR)\\\u003C30mL\u002Fmin\u002F1.73m2), known hepatic insufficiency (Prothrombin Time (PT)\\\u003C70%) or known cardiac disease.\n* History of organic digestive disease (coeliac disease, inflammatory bowel disease, abdominal surgery other than appendectomy or cholecystectomy)\n* Pregnant women, women in labour or breastfeeding mothers\n* Person deprived of liberty by an administrative or judicial decision or person placed under court protection \u002F sub-guardianship or guardianship\n* Patient taking part in another trial \u002F having taken part in another trial within a 4-week period",{"count":178,"type":21},[107],"Irritable bowel syndrome (IBS) affects around 5% of the general population and remains a daily problem in clinicians' practices, with inconsistent efficacy of treatments despite patients' high expectations. Intestinal hyperpermeability and visceral hypersensitivity are the two major components of IBS, and both can disrupt gastrointestinal function and ultimately impair patients' quality of life.\n\nGlutamine is a non-essential amino acid that regulates numerous metabolic pathways and plays a key role in the intestine as it is the preferred substrate for enterocytes and immune cells. A decrease in intestinal glutamine synthetase has been found in IBS, suggesting its involvement in the intestinal permeability and visceral hypersensitivity observed in patients. Ex vivo, glutamine is capable of restoring the expression of tight junction proteins in IBS-D patients. Furthermore, glutamine supplementation is capable of reducing abdominal pain and restoring intestinal permeability disorders in a sub-group of patients with intestinal permeability disorders (post-infectious IBS-D).\n\nThe marine peptides Gabolysat® produced by the Dielen Laboratory have demonstrated their efficacy on intestinal permeability and inflammation in a preclinical model of IBS (Langlois et al. 2023), similar to glutamine supplementation in these animals. The Dielen® Protect product formulated on the basis of the results of this study combines glutamine and Gabolysat® to provide a comfort solution for IBS patients.\n\nOur working hypothesis is that patients suffering from moderate or severe IBS could benefit from oral supplementation with DIELEN Protect to improve the symptoms associated with IBS.\n\n100 patients with IBS (according to Rome IV criteria) will be included in our study.\n\nAll patients will test the treatment for 8 weeks (dielen protect or placebo). The efficacy will be compared between the 2 groups before and after the treatments using validated questionnaires. Therefore, all participants will fill questionnaire before and after 8 weeks of treatments : IBS severity (IBS-SSS), quality of life (GIQLI), Anxiety and depression (HAD), GI symptom related anxiety (VSI), stool frequency and consistancy (BSF scale). Microbiota, metabolomic and short chain fatty acid will be analysed before and after the intervention.",[28],[588],"glutamine","2026-02-19",{"date":591,"type":38},"2026-02-23",{"date":593,"type":38},"2025-04-22",{"date":595,"type":21},"2027-02",{"name":597,"class":45},"University Hospital, Rouen",""]